Completed PHASE4 INTERVENTIONAL 1-arm NCT01088516

Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa

Use of an Aluvia Based Highly Active Antiretroviral Therapy (HAART) Regimen in the Prevention of Mother to Child HIV Transmission (PMTCT) Antepartum, Intrapartum and Postpartum in Africa

Sponsor: Abbott

Conditions HIV

Interventions Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC

Updated 5 times since 2017 Last updated: Jun 22, 2015 Started: Dec 31, 2008 Primary completion: Nov 30, 2011 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01088516, this PHASE4 trial focuses on HIV and remains completed. Sponsored by Abbott, it has been updated 5 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
University of Toronto
University of Zambia

Data source: University of Zambia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lusaka, Zambia